Profile data is unavailable for this security.
About the company
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's lead product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
- Revenue in USD (TTM)27.96m
- Net income in USD-160.28m
- Incorporated2017
- Employees154.00
- LocationAvadel Pharmaceuticals PLCBlock 10-1 Blanchardstown Corporate ParkBallycoolinDUBLIN 15IrelandIRL
- Phone+353 19015201
- Fax+353 15261077
- Websitehttps://www.avadel.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Supernus Pharmaceuticals Inc | 607.52m | 1.32m | 1.69bn | 652.00 | 1,216.17 | 1.83 | 19.57 | 2.78 | -0.0152 | -0.0152 | 10.71 | 16.84 | 0.4077 | 0.9918 | 3.92 | 931,780.70 | 0.0883 | 4.95 | 0.1315 | 6.41 | 86.21 | 88.61 | 0.2166 | 12.84 | 1.43 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
| Catalyst Pharmaceuticals Inc | 398.20m | 71.41m | 1.74bn | 167.00 | 24.16 | 4.07 | 16.66 | 4.36 | 0.6092 | 0.6092 | 3.56 | 3.62 | 0.9417 | 4.63 | 12.45 | 2,384,455.00 | 16.89 | 25.42 | 20.06 | 29.81 | 86.95 | 85.63 | 17.93 | 30.87 | 2.68 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| Myriad Genetics, Inc. | 753.20m | -263.30m | 1.76bn | 2.70k | -- | 2.23 | -- | 2.34 | -3.20 | -3.20 | 9.09 | 8.71 | 0.6423 | 11.22 | 6.98 | 278,963.00 | -22.45 | -- | -25.66 | -- | 68.64 | -- | -34.96 | -- | 1.87 | -342.25 | 0.0469 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
| Inhibrx Inc | 1.80m | -241.36m | 1.79bn | 166.00 | -- | 37.19 | -- | 991.83 | -5.03 | -5.03 | 0.0382 | 0.9184 | 0.006 | -- | 3.53 | 10,843.37 | -80.07 | -77.06 | -93.12 | -93.91 | -- | -- | -13,318.17 | -1,590.91 | -- | -11.00 | 0.8263 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
| Harmony Biosciences Holdings Inc | 617.51m | 137.70m | 1.79bn | 246.00 | 13.63 | 3.48 | 11.06 | 2.90 | 2.32 | 2.32 | 10.39 | 9.08 | 0.7906 | 25.72 | 9.34 | 2,510,207.00 | 17.63 | 7.46 | 20.83 | 9.08 | 79.28 | 80.58 | 22.30 | 10.46 | 3.07 | 31.38 | 0.2694 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 27.96m | -160.28m | 1.81bn | 154.00 | -- | 19.28 | -- | 64.69 | -2.04 | -2.04 | 0.3491 | 0.9768 | 0.188 | -- | 4.52 | 181,577.90 | -107.75 | -40.21 | -156.49 | -47.99 | 96.97 | -- | -573.17 | -374.75 | 3.36 | -13.94 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
| Fusion Pharmaceuticals Inc | 2.07m | -94.90m | 1.82bn | 113.00 | -- | 7.68 | -- | 881.29 | -1.47 | -1.47 | 0.0315 | 2.79 | 0.0082 | -- | 60.82 | 18,300.88 | -37.59 | -35.45 | -40.07 | -38.55 | -- | -- | -4,588.83 | -7,206.24 | -- | -- | 0.1352 | -- | 41.55 | -- | -8.32 | -- | 28.21 | -- |
| Edgewise Therapeutics Inc | 0.00 | -100.16m | 1.82bn | 88.00 | -- | 4.31 | -- | -- | -1.57 | -1.57 | 0.00 | 4.53 | 0.00 | -- | -- | 0.00 | -28.33 | -- | -29.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -89.62m | 1.83bn | 93.00 | -- | 4.03 | -- | -- | -2.51 | -2.51 | 0.00 | 9.76 | 0.00 | -- | -- | 0.00 | -30.91 | -- | -33.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| Syndax Pharmaceuticals Inc | 0.00 | -209.36m | 1.87bn | 112.00 | -- | 3.38 | -- | -- | -2.96 | -2.96 | 0.00 | 6.53 | 0.00 | -- | -- | 0.00 | -37.72 | -27.90 | -40.93 | -30.15 | -- | -- | -- | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
| Beam Therapeutics Inc | 377.71m | -132.53m | 1.90bn | 436.00 | -- | 1.92 | -- | 5.04 | -1.87 | -1.87 | 4.90 | 12.02 | 0.2697 | -- | -- | 866,305.10 | -9.46 | -24.54 | -11.17 | -29.26 | -- | -- | -35.09 | -211.96 | -- | -- | 0.0005 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Ginkgo Bioworks Holdings Inc | 251.46m | -892.87m | 1.94bn | 1.22k | -- | 1.74 | -- | 7.72 | -0.459 | -0.459 | 0.1293 | 0.5482 | 0.1196 | 24.49 | 5.01 | 206,449.10 | -42.47 | -- | -46.17 | -- | 78.52 | -- | -355.08 | -- | 6.11 | -1,703.31 | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Lindbrook Capital LLCas of 31 Mar 2024 | 98.00 | 0.00% |
| Avior Wealth Management LLCas of 31 Mar 2024 | 42.00 | 0.00% |
| Abante Asesores Gesti�n SGIIC SAas of 30 Jun 2023 | 0.00 | 0.00% |
